Metastatic colorectal cancer.

Area of Science:

• Oncology
• Gastroenterology
• Cancer Research

Background:

• Metastatic colorectal cancer (mCRC) poses a significant global health challenge.
• Advances in cytotoxic agents have improved survival for mCRC patients.
• Optimizing chemotherapy efficacy and tolerability requires further investigation.

Purpose of the Study:

• To review current strategies for managing metastatic colorectal cancer.
• To explore the role of chemotherapy, hepatic resection, and targeted therapies in mCRC treatment.
• To address the ongoing challenge of maximizing treatment benefits while minimizing toxicity.

Main Methods:

• Review of recent advancements in colorectal cancer treatment modalities.
• Analysis of data on cytotoxic chemotherapy, surgical interventions (hepatic resection), and targeted therapies.
• Discussion of emerging therapeutic targets such as Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF).

Main Results:

• Newer cytotoxic agents have enhanced survival outcomes in metastatic colorectal cancer.
• Hepatic resection offers potential for long-term survival in select patients.
• Targeted therapies, including inhibitors of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor, show promising results.

Conclusions:

• Improving survival in metastatic colorectal cancer involves a multi-faceted approach.
• Chemotherapy optimization, surgical options, and targeted molecular therapies are crucial.
• Further research is needed to balance treatment efficacy with acceptable toxicity for optimal patient care.